SBC Medical Group Holdings Incorporated (NASDAQ:SBC - Get Free Report)'s share price dropped 3.4% on Thursday . The stock traded as low as $4.48 and last traded at $4.48. Approximately 118,136 shares changed hands during mid-day trading, an increase of 92% from the average daily volume of 61,540 shares. The stock had previously closed at $4.64.
SBC Medical Group Trading Up 0.2%
The company has a debt-to-equity ratio of 0.06, a current ratio of 2.79 and a quick ratio of 2.76. The firm has a 50 day moving average of $3.96 and a two-hundred day moving average of $4.51.
SBC Medical Group (NASDAQ:SBC - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.11 by $0.10. The business had revenue of $47.33 million for the quarter, compared to analysts' expectations of $51.52 million. On average, analysts expect that SBC Medical Group Holdings Incorporated will post 5.02 EPS for the current fiscal year.
SBC Medical Group Company Profile
(
Get Free Report)
SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand.
Featured Articles
Before you consider SBC Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SBC Medical Group wasn't on the list.
While SBC Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
